Drug class
CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapy
Mechanism of action
Autologous CD4-positive and CD8-positive T cells are genetically modified to express an anti-CD19 chimeric antigen receptor containing 4-1BB costimulatory and CD3-zeta signalling domains. After infusion, the cells recognise CD19-expressing B-lineage tumour cells and mediate T-cell activation, proliferation and cytotoxic killing.
General use cases
- Treatment of adults with specified large B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, in the treatment settings defined by the current product label.
- The current US label includes selected earlier-line and later-line settings; primary central nervous system lymphoma is not an indicated use.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
